AnergiX AG284 myelin basic protein complexed to HLA-DR2 major histocompatibility complex molecule: Phase I

ANRG said that a placebo-controlled Phase I dose-escalation study in 33 patients showed safety and tolerability of its autoimmune treatment to suppress T cells specifically involved in the disease pro...